Ultracet Generics Launch: Par Goes "At Risk," Ivax Has "Authorized" Generic
This article was originally published in The Pink Sheet Daily
Executive Summary
Patent litigation between Par and J&J is pending in Newark, N.J. federal court. Par received ANDA approval for the tramadol/acetaminophen combination the same day the 30-month stay expired.
You may also be interested in...
Accupril Generics Come Off The Market Following Preliminary Injunction
Teva and Ranbaxy plan to appeal the district court ruling in favor of Pfizer to the federal appeals court. Pfizer said it will seek damages for lost Accupril sales since the December launch of Teva/Ranbaxy’s quinapril.
Mylan Encounters "Irrational Pricing" In Duragesic Generics Market
Pricing pressure for fentanyl transdermal resulted from "premarketing" by other ANDA filers and regulatory uncertainty that gave "authorized" generic marketer Sandoz an advantage, Mylan CEO says. Timing of other generic entrants and potential supply problems for J&J/Sandoz could allow Mylan to recover lost profits.
Andrx Expects Concerta "Authorized" Generic From J&J's Patriot Unit, Third Party
In a citizen petition, Andrx requests FDA re-evaluate its policy concerning the marketing of "authorized" generic versions of brand drugs. Petition urges the agency to seek formal input from FTC and Justice Department on potential anticompetitive effects.